Would you consider restarting a SGLT2i at a reduced dose in a patient who you previously discontinued the medication because of an associated significant decline in eGFR?  

Restarting an SGLT2i in a patient after a severe episode of AKI requires careful decision-making and patient agreement. If the AKI episode was deemed related to volume depletion (hemodynamically mediated AKI), I restart the SGLT2i at a lower dose. At the same time, I re-counsel the patent on fluid ...